Recombinant Human Disintegrin And Metalloproteinase Domain-Containing Protein 33 (ADAM33) Protein (His)

Beta LifeScience SKU/CAT #: BLC-00982P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Disintegrin And Metalloproteinase Domain-Containing Protein 33 (ADAM33) Protein (His)

Beta LifeScience SKU/CAT #: BLC-00982P
Regular price $1,404.00 Sale price $299.00Save $1,105
/
Size

Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Disintegrin And Metalloproteinase Domain-Containing Protein 33 (ADAM33) Protein (His) is produced by our Baculovirus expression system. This is a protein fragment.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb Q9BZ11
Target Symbol ADAM33
Synonyms (ADAM 33)
Species Homo sapiens (Human)
Expression System Baculovirus
Tag C-6His
Target Protein Sequence VLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDT
Expression Range 30-701aa
Protein Length Partial
Mol. Weight 78.0 kDa
Research Area Cell Biology
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Subcellular Location Membrane; Single-pass type I membrane protein.
Database References
Associated Diseases Asthma (ASTHMA)
Tissue Specificity Expressed in all tissues, except liver, with high expression in placenta, lung, spleen and veins.

Gene Functions References

  1. This study suggests that metabolites of phthalate such as MEHHP, MECPP, MEOHP and Sigma4MEHP may increase the intron 1 methylation level to elevate ADAM33 gene expression and have a protective effect on reducing the risk of breast cancer. PMID: 30226539
  2. There was no significant difference in ADAM33 genotype and allele distributions between psoriasis and control groups (p > 0.05). CONCLUSIONS: ADAM33 V4 C/G rs2787094 polymorphism was not associated with psoriasis risk in the Turkish population. PMID: 30160137
  3. A lower level of ADAM33 was also correlated with shorter overall survival and metastasis-free survival and was considered an independent prognostic factor suggesting that ADAM33 is a novel molecular biomarker of Triple-negative breast cancer and basal-like phenotype that might be useful as a prognostic factor. PMID: 28294120
  4. IL4RA and ADAM33 variants may be risk markers of asthma exacerbations in type-2 inflammatory endotype. Precise endotyping may facilitate the identification of genetic risk markers of asthma exacerbations. PMID: 28326636
  5. Collectively, our findings suggest that 1,25(OH)2D3 inhibits VEGF-induced ASM cell proliferation by suppressing VEGFR2 and ERK1/2 activation and downregulating ADAM33. Further studies of these mechanisms are needed to facilitate the development of treatments for smooth muscle hyperplasia-associated diseases of the airway such as asthma. PMID: 28056993
  6. meta-analysis suggested that ADAM33 polymorphisms rs2280091, rs2280090, rs2787094, rs44707 and rs528557 were significantly associated with a high risk of childhood asthma PMID: 28876365
  7. There was a significant difference in the frequency of ADAM33 V4 polymorphism in both, asthmatic and COPD patients groups. No significant differences were found for T1 polymorphism. However, there were significant differences when haplotypes and diplotypes of ADAM33 V4/T1 were compared in all three groups. It can be concluded that the polymorphism V4 of ADAM33 is associated with asthma or COPD in Venezuelan patients. PMID: 28429897
  8. Evidence from this meta-analysis demonstrates that ADAM33 T1 polymorphism might be associated with increased susceptibility to asthma among Asian children and that ADAM33 F + 1, T2, S2, or V4 polymorphism may be unrelated to susceptibility of childhood asthma. PMID: 28285393
  9. enhances ADAM-33 expression and airway smooth muscle cell proliferation PMID: 27579513
  10. An association between ADAM33 gene polymorphism and impaired lung functions was detected in wood dust-exposed workers. PMID: 26500222
  11. This meta-analysis demonstrates that the ADAM33 gene polymorphisms confer susceptibility to allergic rhinitis PMID: 26619918
  12. findings suggest that genetic variants of ADAM33 gene may play important roles in asthma susceptibility in the Punjabi population of Pakistan PMID: 26666372
  13. We investigated the influence of ADAM33 polymorphisms on the serum levels of ADAM33 and the susceptibility to pediatric asthma in the Chinese Han population PMID: 26291893
  14. ADAM33 and ADAM12 genetic polymorphisms and their expression in Egyptian children with asthma PMID: 26553447
  15. the ADAM33 T1, T2, S1, Q-1, F+1 and ST+5 six locus polymorphisms association with the risk of COPD. PMID: 25280544
  16. a compromised ADAM33 gene may be implicated in the progression of wheeze into childhood asthma PMID: 25768087
  17. Our results suggest that the ADAM33 V4 polymorphism increases the risk of asthma. PMID: 25730038
  18. the intima+media of IPAH vessels, collagens (COL4A5, COL14A1, and COL18A1), matrix metalloproteinase (MMP) 19, and a disintegrin and metalloprotease (ADAM) 33 were higher expressed, whereas MMP10, ADAM17, TIMP1, and TIMP3 were less abundant. PMID: 25840998
  19. The results of this study suggest that these proteins play important roles in pulmonary inflammatory reactions elicited against etiological viral agents. PMID: 25453333
  20. Association between ADAM33 polymorphisms and susceptibility with adult and childhood asthma among Jordanians. PMID: 25313536
  21. ADAM33 was involved in the pathogenesis of chronic obstructive pulmonary disease in an East Asian population by affecting airway inflammation and immune response. PMID: 25369941
  22. A significant association was found between the T1 ADAM33 polymorphism and chronic obstructive pulmonary disease in the Chinese population in both dominant and recessive models, with no association with S2 ADAM33 polymorphism. (Meta-analysis) PMID: 25158257
  23. ADAM33 haplotypes (a1, a2, a3) are associated with severity of airway hyperreactivity and are significantly more often transmitted in the paternal line PMID: 23640030
  24. The proteins identified in this study were enriched for various mechanisms that are involved in airway hyperresponsiveness, and through the interaction with ADAM33, they may have potential relevance in asthma. PMID: 25155083
  25. ADAM33 rs628977G>A was marginally associated with a decreased risk of idiopathic pulmonary fibrosis in a recessive model. PMID: 24728305
  26. Apparently, the investigated polymorphisms of VDBP, MMP1, ADAM33, and IL8 contribute to the genetic susceptibility to chronic bronchitis induced by dust and toxic agents. PMID: 25739290
  27. Results suggest that polymorphisms T1, T2, and V4 in ADAM33 may contribute to the susceptibility to asthma. PMID: 25036518
  28. Our data suggest that the ADAM33 polymorphisms may be associated with Psoriasis in the northeastern Chinese population PMID: 24562625
  29. ADAM33 S1 polymorphism is a risk factor for COPD among the Chinese and smoking populations, and that Q-1 polymorphism is a risk factor for COPD among the overall populations. PMID: 24422987
  30. Polymorphisms in the ADAM33 gene may contribute to susceptibility of mite-sensitized persistent allergic rhinitis in the Chinese population. PMID: 24751681
  31. A meta-analysis suggests that the ADAM33 rs528557 C>G polymorphism may contribute to susceptibility to asthma. PMID: 25068505
  32. Meta-analysis suggested that S1 (rs3918396) polymorhism of ADAM33 is associated with increased risk of COPD in Asian (China) but not in Caucasians. PMID: 23902466
  33. Seven single nucleotide polymorphisms (SNPs) in ADAM33 were associated with chronic obstructive pulmonary disease in the Mongolian population of China. Even after Bonferroni correction, SNPs S2, S1, Q-1 and F+1 remained significant. PMID: 24191661
  34. ADAM33 polymorphisms are correlated with asthma and may be the underlying genetic basis of the association between asthma and palm dermatoglyphic patterns. PMID: 24141861
  35. ADAM33 is a pleiotropic gene that is associated with all-cause, chronic obstructive pulmonary disease, and cardiovascular mortality, independent of potential confounders. PMID: 23861802
  36. Single nucleotide polymorphisms in ADAM33 gene is associated with the risk of adult glioma. PMID: 23525950
  37. A higher expression of ADAM33 protein was seen in asthma patients compared to controls. PMID: 23640557
  38. The polymorphisms in the ADAM33 gene are associated with susceptibility to allergic rhinitis in the Jordanian population. PMID: 24035932
  39. Genetic polymorphism in the IL-4 promoter, ADRbeta2, and ADAM33 is associated with asthma. PMID: 23245479
  40. association of 11 SNPs of the ADAM33 and 6 of the STAT6 and their haplotypes with IgE levels and asthma PMID: 22660217
  41. This meta-analysis indicates that the rs2280091, rs2787094, rs511898, rs2280090, and rs2280089 polymorphisms in the ADAM33 gene are risk factors for asthma, especially in the Asian population. PMID: 23380143
  42. The single nucleotide polymorphisms (F+1 C/T, T2 G/A and V4 C/G) of the ADAM33 gene may be the causal variants in asthma disease. PMID: 21689380
  43. Experiments showed that the 14 CpG sites in exon 9 of the ADAM33 gene were highly methylated (100%) in all individuals with asthma. PMID: 23257708
  44. The ADAM33 ST+4 polymorphism is associated with asthma in Asians.[meta-analysis] PMID: 23612257
  45. Consistent interaction between genetic variants and environmental tobacco exposures was for ADAM33 SNP rs512625 in relation to asthma severity in asthmatic children. PMID: 23331525
  46. ADAM33 SNP rs612709 and the CCGGAAGA haplotype may be associated with asthma. Smoking may modify the associations between SNPs rs628977 and rs528557 and asthma. PMID: 22583515
  47. This meta-analysis demonstrates that the ADAM33 T1 polymorphism confers susceptibility to asthma in Asians, but no association was found between the ADAM33 T2 and ST+7 polymorphisms and asthma susceptibility. PMID: 22851202
  48. SNPs, T+1, S+1 and V - 3 do not individually confer any significant risk of asthma or its severity, but haplotype analysis suggests all three polymorphisms together play an important role in the disease of asthma PMID: 22989201
  49. ADAM33 polymorphisms, but not S1 or ST+4, were significantly associated with asthma development in Saudi children, like those reported for white and Hispanic populations in the United States PMID: 22871616
  50. 1,25-(OH)(2)D(3) has a direct inhibitory effect on passively sensitized human airway smooth muscle cells in vitro, including the inhibition of cell proliferation and the expressions of MMP-9 and ADAM33. PMID: 21781516

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed